The trace
Cell-free DNA in blood can include a small tumour-derived fraction called ctDNA.
Technology
A blood test reveals the signal
A timeline shows how it changes
Fidelion found VitaGuard: a functioning tumour-naive approach designed to start from blood, then follow a molecular signal over time.
A signal worth following
Blood can carry a trace
whose meaning emerges over time
Cells release fragments of DNA into the blood. A small fraction may come from a tumour; this is circulating tumour DNA, or ctDNA.
After treatment, repeat results may reveal a direction that one result cannot. That molecular view is intended to add context alongside imaging, pathology and clinical judgment—not replace them.
What may remain
MRD is molecular evidence that a small amount of disease may remain after treatment.
The direction
A series may show whether a signal appears, clears, persists, rises or falls.
The context
Molecular results add information to the established picture of each patient.
Tumour-naive by design
VitaGuard™ MRD
A fixed-panel blood test designed to look for residual cancer signals without first sequencing tumour tissue to create a patient-specific assay.
The larger possibility
Longitudinal insight
Repeat measurements may support clearer trends, stronger research and, after appropriate validation, future analytical tools.